drTarget portfolio target-disease associations for bioprocesses DrTarget’s AI-Powered Indication Expansion for Biological Processes

DrTarget’s AI-Powered Insights into Biological Processes

DrTarget has mapped 125 target proteins from PubChem screens across 24 bioprocesses, leveraging data from Open Targets. By applying machine learning models and AI-driven analytics, we identify novel molecular targets and bioprocess-level interactions that can drive breakthroughs in drug discovery, biotechnology, and synthetic biology.

Our AI-powered approach enables:

✔ Identification of critical molecular players in key bioprocesses
✔ Drug repurposing and bioengineering strategies
✔ Pathway analysis to optimize therapeutic intervention points

By integrating AI-based virtual screening, multi-source validation, and topological analysis, DrTarget provides deep insights into biological systems that can accelerate biopharma innovation and precision medicine applications.

Target-disease associations for bioprocesses.

Check best scored target-disease associations in table:

entries per page

Search:

PubChemAssay	program	diseaseName	assayType	testedCompounds	activeCompounds	associationScore	numberOfEvidences

PubChemAssay	program	diseaseName	assayType	testedCompounds	activeCompounds	associationScore	numberOfEvidences
High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6)	TRPC6	trait in response to prednisolone	targetBased	305610	3253	0.59	50
High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6)	TRPC6	trait in response to prednisolone	targetBased	305610	382	0.59	50
CYP2C9 Assay	CYP2C9_inhibitors	trait in response to phenytoin	targetBased	95858	18730	0.46	3
HTS Assay for Activators of Cytochrome P450 2A9	CYP2C9_activators	trait in response to phenytoin	targetBased	95858	1368	0.46	3
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	social behavior	targetBased	324747	1043	0.41	2
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	insulin secretion	targetBased	405130	6428	0.41	2
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	insulin secretion	targetBased	373462	23	0.41	2
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	insulin secretion	targetBased	405130	6428	0.41	2
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	reproductive process	targetBased	86095	1151	0.21	9
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	reproductive process	targetBased	86095	1442	0.21	9

Showing 1 to 10 of 112 entries

Some of these associations have also gone through clinical trials, as those in the graph below.

Find clinical trials details in table. Use scroll bar or search funtion to select specific drugs, molecular targets or diseases.

entries per page

Search:

BioAssay Name	program	gene	protName	diseaseName	molname	assayMode	clinicalPhase	clinicalStatus	studyStartDate	url	score	variantEffect	directionOnTrait	studyStopReason

BioAssay Name	program	gene	protName	diseaseName	molname	assayMode	clinicalPhase	clinicalStatus	studyStartDate	url	score	variantEffect	directionOnTrait	studyStopReason
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	memory	PROPRANOLOL	targetBased	1	Completed		https://clinicaltrials.gov/study/NCT00889096	0.1	LoF	protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	drug toxicity	ACETAMINOPHEN	targetBased	1	Recruiting	15/01/2024	https://clinicaltrials.gov/study/NCT06214468	0.1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	aging	ESTRADIOL	targetBased	2	Completed	01/12/2002	https://clinicaltrials.gov/study/NCT00220454	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	aging	ESTRADIOL	targetBased	2	Completed	01/12/2002	https://clinicaltrials.gov/study/NCT00220454	0.2	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	aging	ESMOLOL	targetBased		Completed	02/02/2022	https://clinicaltrials.gov/study/NCT04181606	0.05	LoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	aging	CHOLECALCIFEROL	targetBased	2	Unknown status	01/07/2014	https://clinicaltrials.gov/study/NCT02222649	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	aging	PSILOCYBINE	targetBased	1	Not yet recruiting	01/04/2025	https://clinicaltrials.gov/study/NCT06367738	0.1	GoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	aging	DASATINIB	targetBased	2	Active, not recruiting	16/12/2020	https://clinicaltrials.gov/study/NCT04946383	0.2	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	aging	DASATINIB	targetBased	1	Completed	20/05/2022	https://clinicaltrials.gov/study/NCT05422885	0.1	LoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	aging	OXYTOCIN	targetBased	2	Withdrawn	01/01/2019	https://clinicaltrials.gov/study/NCT02409862	0.2	GoF	protect	Technical issues preventing recruitment.

Showing 1 to 10 of 19 entries

entries per page

Search:

BioAssay Name	program	gene	protName	diseaseName	molname	assayMode	clinicalPhase	clinicalStatus	studyStartDate	url	score	variantEffect	directionOnTrait	studyStopReason

BioAssay Name	program	gene	protName	diseaseName	molname	assayMode	clinicalPhase	clinicalStatus	studyStartDate	url	score	variantEffect	directionOnTrait	studyStopReason
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	memory	PROPRANOLOL	targetBased	1	Completed		https://clinicaltrials.gov/study/NCT00889096	0.1	LoF	protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	drug toxicity	ACETAMINOPHEN	targetBased	1	Recruiting	15/01/2024	https://clinicaltrials.gov/study/NCT06214468	0.1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	aging	ESTRADIOL	targetBased	2	Completed	01/12/2002	https://clinicaltrials.gov/study/NCT00220454	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	aging	ESTRADIOL	targetBased	2	Completed	01/12/2002	https://clinicaltrials.gov/study/NCT00220454	0.2	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	aging	ESMOLOL	targetBased		Completed	02/02/2022	https://clinicaltrials.gov/study/NCT04181606	0.05	LoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	aging	CHOLECALCIFEROL	targetBased	2	Unknown status	01/07/2014	https://clinicaltrials.gov/study/NCT02222649	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	aging	PSILOCYBINE	targetBased	1	Not yet recruiting	01/04/2025	https://clinicaltrials.gov/study/NCT06367738	0.1	GoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	aging	DASATINIB	targetBased	2	Active, not recruiting	16/12/2020	https://clinicaltrials.gov/study/NCT04946383	0.2	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	aging	DASATINIB	targetBased	1	Completed	20/05/2022	https://clinicaltrials.gov/study/NCT05422885	0.1	LoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	aging	OXYTOCIN	targetBased	2	Withdrawn	01/01/2019	https://clinicaltrials.gov/study/NCT02409862	0.2	GoF	protect	Technical issues preventing recruitment.

Showing 1 to 10 of 19 entries

Partner with DrTarget for AI-Optimized Screening

We welcome collaborations with biotech companies, research institutions, and pharmaceutical partners looking to leverage AI for drug discovery. Get in touch to explore custom screening solutions and accelerate your research.

drTarget portfolio target-disease associations for bioprocesses

DrTarget’s AI-Powered Insights into Biological Processes

Our AI-powered approach enables:

✔ Identification of critical molecular players in key bioprocesses✔ Drug repurposing and bioengineering strategies✔ Pathway analysis to optimize therapeutic intervention points

By integrating AI-based virtual screening, multi-source validation, and topological analysis, DrTarget provides deep insights into biological systems that can accelerate biopharma innovation and precision medicine applications.

Check best scored target-disease associations in table:

Some of these associations have also gone through clinical trials, as those in the graph below.

Partner with DrTarget for AI-Optimized Screening

We welcome collaborations with biotech companies, research institutions, and pharmaceutical partners looking to leverage AI for drug discovery. Get in touch to explore custom screening solutions and accelerate your research.

✔ Identification of critical molecular players in key bioprocesses
✔ Drug repurposing and bioengineering strategies
✔ Pathway analysis to optimize therapeutic intervention points